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Abstract
MR cholangiopancreatography (MRCP) is an imaging tech-
nique that has evolved over the past 2 decades and that con-
tinues to have a fundamental role in the non-invasive detection
of morphologic features of the pancreatic ducts. In several
studies, MRCP has shown a good correlation with endoscopic
retrograde cholangiopancreatography in the evaluation of dis-
eases and anatomic variants of the pancreatic ductal system.
However, in physiologic conditions the pancreatic ducts are
not always easily recognisable. More recently, secretin-
enhanced MRCP protocols have been developed for a more
complete assessment of pancreatic ducts and glandular func-
tion, including monitoring of pancreatic flow dynamics and
duodenal filling after pancreatic hormonal stimulation with
secretin. The injection of this hormone causes temporary di-
lation of the pancreatic ducts, principally by increasing pan-
creatic exocrine secretions, and thus improving MRCP detec-
tion of the ducts and characterisation of pancreatic disorders
and allowing the assessment of the exocrine pancreatic re-
serve. The purpose of this pictorial review is to summarise
the technical aspects of secretin-stimulated MRCP, to report
the secretin-stimulated MRCP findings of pancreatic duct ab-
normalities and to review the diagnostic capabilities of
secretin-stimulatedMRCP in various pancreatic ductal system
conditions.
Main Messages
• MRCP has a fundamental role in the non-invasive detection
of pancreatic ducts.
• In physiologic conditions pancreatic ducts are not always
well detected on MRCP.
• Secretin injection causes temporary dilation of pancreatic
ducts and thus improves MRCP detection.
• Secretin-stimulated MRCP may allow the assessment of the
exocrine pancreatic reserve.
• Secretin increases the diagnostic capabilities of MRCP for
evaluating pancreatic disorders.
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Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is
still considered the most sensitive and specific technique for
the assessment of the pancreatic ductal system. However,
ERCP is an invasive method that can potentially cause com-
plications, though rarely severe. Another disadvantage is that
it does not provide information on extra-ductal lesions and
does not allow the visualisation of the obstructed segment in
the event of total duct obstruction.
MR cholangiopancreatography (MRCP) is a non-invasive
imaging technique that accurately detects the morphologic
features of the pancreatic ducts. In several studies [1–4],
MRCP demonstrated a good correlation with ERCP in the
evaluation of disease and anatomic variants of the pancreatic
ductal system. However, in physiological conditions the pan-
creatic ducts, particularly the side branches, are not always
easily recognisable [2, 5].
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Secretin is a peptide hormone produced by the intestinal
mucosa, especially in the duodenum, and stimulates the fluid
volume secreted by the exocrine pancreas. The increased vol-
ume causes temporary dilation of the pancreatic ducts and
allows a better visualisation of them in MRCP; this condition
can improve the detection and characterisation of pancreatic
duct disorders [5–9].
More recently, secretin-enhanced MRCP protocols have
been developed for a more complete assessment of the pan-
creatic ducts and glandular function, including monitoring of
pancreatic flow dynamics and duodenal filling after pancreatic
hormonal stimulation with secretin. Furthermore, some au-
thors are also exploring the feasibility of this technique in
the remnant pancreas after pancreatoduodenectomy and in
the pancreatic graft [10–12].
In this pictorial review, we present our experience with
secretin-stimulated MRCP (SS-MRCP) findings observed in
patients with diagnosed or suspected pancreatic disease, fo-
cussing on the main clinical applications of this MR tech-
nique. All these clinical cases were carried out at a large uni-
versity hospital specialising in hepato-biliary diseases.
MR imaging technique
At our institution, MR imaging is performed with supercon-
ductive 1.5-T and 3.0-T devices (Signa HDx and GE-
DISCOVERY MR750; GE Healthcare, Milwaukee, WI,
USA) and phased-array multi-channel coils. All patients fast
for at least 4–6 h prior to the examination and, 10 min before
MRI, ingest a super-paramagnetic suspension (Lumirem®
100 ml, Guerbet) to suppress the signal intensity of overlap-
ping fluid-containing organs. As an alternative for ferumoxsil
suspensions, 5 ml of gadolinium-DTPA mixed in 75 ml of
distilled water can be used to shorten the T2 time by acting
as a negative T2 agent. Scopolamine methyl-bromide
(Buscopan® 20 mg/ml, Boehringer Ingelheim) is intramuscu-
larly administered immediately before starting the examina-
tion in order to avoid peristaltic artefacts.
The imaging protocol begins with axial, breath-hold, with
and without fat-suppressed spoiled gradient-echo (SPGR) T1-
weighted images followed by axial, respiratory-triggered, fat-
suppressed, fast spin-echo (FSE) T2-weighted and/or axial,
breath-hold, single-shot fast spin-echo (SSFSE) T2-weighted
sequences.
Conventional MRCP is usually performed by using two
techniques: respiratory-triggered, thin-collimation (2.4 mm
thickness/-1.2 mm) three-dimensional FRFSE T2w sequences
in the coronal plane and breath-hold, thick-slab (40-60 mm),
single-shot FSE T2w sequences performed in the coronal and
coronal oblique projections.
After the acquisition of the first image, secretin (Secrelux®,
Sanochemia; 1 cU/kg body/weight) is injected intravenously
in order to stimulate the pancreas to produce exocrine secre-
tion. Secretin is administered via a slow intravenous injection
for 1 min to avoid the potential adverse effect of abdominal
pain that can occur with a bolus injection. SS-MRCP is per-
formed using a coronal breath-hold, thick-slab, SSFSE T2w
sequence covering the pancreas and adjacent small bowel;
single-slice image acquisition is repeated every 30 s up to
15 min. Secretin has a very favourable safety and tolerability
profile causing nausea, flushing or vomiting in only 0.5 % of
patients. The only contraindication to the use of secretin docu-
mented by the manufacturer is acute pancreatitis. However in
our institution secretin is used in patients with mild acute pan-
creatitis but is avoided in those with severe pancreatitis. The
administration of secretin is therefore usually very well
tolerated.
The peak effect of intravenous secretin administration is
usually observed at 3-5 min after injection. At this time the
calibre of the main pancreatic duct can increase by 1 mm or
more compared with the baseline measurement and the side
branches may become visible and be helpful for the diagnosis
[13].
A functional evaluation of the exocrine pancreatic reserve
can be performed by a semi-quantitative image analysis of the
duodenal filling on the basis of pancreatic secretion after se-
cretin stimulation. The pancreatic fluid outflow is visually
analysed on the image time series by the observers. The duo-
denal filling volume can be graded according to the scale (0–
3) derived by Matos et al. [2] (Fig. 1).
Clinical applications
Anatomic variants
SS-MRCP improves the visualisation of the full length of the
main pancreatic duct resulting in higher sensitivity and
specificity in detecting congenital anomalies/malformations
and in confirming or excluding entities such as pancreas
divisum (PD) and anomalous pancreatico-biliary junction
(APBJ).
PD is the most common congenital anatomical variant of
pancreatic ductal development (about 15 %–20 % of patients
with unexplained pancreatitis have been found to have PD,
whereas only 5 %–10 % of the general population present
such malformation) caused by the lack of fusion between the
ventral and dorsal pancreatic ducts during the 6th-8th week of
gestation. Because the major part of the pancreatic secretion
must flow through the minor pancreatic duct, this could pre-
dispose to obstructive pancreatopathy causing pancreatitis and
pancreatic-type pain or even the development of severe chron-
ic pancreatitis [14, 15].
Another anatomic variant, called Bincomplete pancreas
divisum^ (IPD), shares the feature of excretion of the major
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fraction of pancreatic secretions via the dorsal duct orifice.
IPD is less associated with pancreatitis than complete PD,
since high pressure in the dorsal pancreatic duct system can
decrease via a connection to the ventral duct [12, 15, 16].
SS-MRCP and MRI can serve as a comprehensive diag-
nostic tool without radiation for the diagnosis of PD (Fig. 2) or
IPD (Fig. 3), whereas the ERCP can be reserved for clinical
conditions that require interventional procedures for therapeu-
tic purposes [17].
APBJ is a rare congenital anomaly in which the pancreatic
and biliary ducts are joined outside the duodenal wall [15],
which may be diagnosed by distention of the gallbladder dur-
ing SS-MRCP.
Santorinicele is a cystic dilation of the distal dorsal duct,
just proximal to the minor papilla, and is believed to result
from a combination of relative obstruction and weakness of
the distal duct wall, either acquired or congenital.
Santorinicele has been suggested as a possible cause of rela-
tive stenosis of the accessory papilla that may become clini-
cally relevant when it occurs in association with PD or IPD,
resulting in recurrent episodes of acute pancreatitis.
According to some authors, SS-MRCP is effective in diag-
nosing the presence of Santorinicele in patients affected by
unexplained recurrent episodes of acute pancreatitis, who
might benefit from endoscopic sphinterotomy of the minor
papilla [15, 18].
Chronic pancreatitis
Chronic pancreatitis is defined as a continuing inflammatory
destruction of pancreatic tissue that results in irreversible dam-
age to the parenchyma and ductal system, causing loss of the
exocrine and/or endocrine function. Diagnosis is made by
clinical history, testing of the pancreatic exocrine function
and imaging.
As to the evaluation of the pancreatic exocrine function, the
most sensitive diagnostic tool to detect chronic pancreatitis at
its earliest stage is the secretin-stimulated endoscopic pancre-
atic function testing (ePFT): pancreatic exocrine reserve is
measured by duodenal aspiration after direct stimulation of
the gland. The disadvantages of this test include its invasive-
ness, long procedure time and sedation of the patient during
the procedure. A reliable non-invasive alternative technique is
the SS-MRCP, where imaging findings (reduced duodenal
filling grade and reduced increase in pancreatic duct caliber)
are comparable to the results of ePFT [19].
MRI allows the evaluation of early fibrotic changes, glan-
dular volume depletion or atrophy, and pancreatic progressive
Fig. 1 a–cNormal findings. MRCP performed before secretin injection shows a normal main pancreatic duct (a), which demonstrates a regular dilation
3 min after secretin stimulation (b) and normal duodenal filling beyond the genu inferius after 15 min (c)
Fig. 2 a–c Complete pancreas divisum. Before secretin stimulation,
MRCP (a) reveals only the dorsal pancreatic duct. MRCP obtained
3 min after secretin injection (b) demonstrates both the ventral and the
dorsal pancreatic duct, without connection between them and prompt
outflow of pancreatic secretion via the minor papilla, corresponding to
pancreas divisum with dominant dorsal duct. MRCP obtained 15 min
after secretin injection (c) shows normal duodenal filling beyond the
genu inferius
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enhancement that peaks on the portal-venous or interstitial
phase.
However, parenchymal changes might be preceded by duc-
tal changes in chronic pancreatitis.
MRCP findings in early chronic pancreatitis often display a
normal main pancreatic duct because of the underestimation
of ductal size. Some investigators reported that patients with
abnormalMR imaging findings but normalMRCPmight ben-
efit from dynamic SS-MRCP. SS-MRCP may reveal ductal
abnormalities otherwise not detected onMRCP alone because
of improved visualisation, and it provides images comparable
to ERCP according to the Cambridge classification [20]. SS-
MRCP has been reported to show ductal changes such as an
increased number of side branch ectasia, irregular morphology
of the pancreatic duct and/or decreased pancreatic duct com-
pliance after secretin stimulation (Fig. 4).
Discrepancies between standard MRI/MRCP findings and
pancreatic exocrine function exist. In a study by Balci et al.,
the severity of pancreatic duct and side branch changes were
the same in both groups of normal and abnormal exocrine
function values. A patient with normal pancreatic exocrine
function may have abnormal pancreatic ductal changes con-
sistent with chronic pancreatitis. Patients with chronic
pancreatitis may have maintained the pancreatic exocrine
function [19]. Any stricture or obstruction in the distal duct
or ampulla can increase the distention of the upstream portion
of the duct in response to secretin (Fig. 5). Because strictures
are often found in patients with chronic pancreatitis, ductal
distention in such cases can be falsely reassuring. On the other
hand, ductal distention in response to secretin administration
is not seen in normal patients who have undergone prior pan-
creatic sphincterotomy because of the lack of pressure at the
orifice [16]. Though the technique does not always allow a
correct evaluation of the exocrine pancreatic function, it must
be stressed again that SS-MRCP is a non-invasive technique
and its results are comparable to those of ePFT.
Focal pancreatic lesions
The detection of a focal enlargement or distortion of the nor-
mal contour of the pancreas is a common finding for radiolo-
gists who treat pancreatic diseases. Patients with such focal
enlargements of the pancreas will have a conventional pancre-
atic carcinoma (PC) even if pathognomonic features of pan-
creatic carcinomas are still lacking, while a small percentage
of them may have an inflammatory pancreatic mass (IPM).
Fig. 3 a–c Incomplete pancreas divisum. Before secretin-stimulation,
MRCP (a) shows both the dorsal and the ventral pancreatic duct
connected between them and the major and minor papilla. After
secretin injection (b, c) two other secondary ducts and another cranial
accessory papilla are visualised (arrows), with initial outflow of
pancreatic secretion via the accessory papilla
Fig. 4 a–c Mild chronic pancreatitis. MRCP obtained before secretin
injection (a) shows a normal main pancreatic duct. Three minutes after
secretin stimulation (b), MRCP reveals side branch dilation, particularly
at the level of the head and tail diagnosed as mild chronic pancreatitis.
MRCP obtained 15 min after secretin injection (c) demonstrates normal
duodenal filling beyond the genu inferius, interpreted as preserved
pancreatic exocrine reserve
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Although most patients with IPM have somewhat charac-
teristic histories, such as alcohol abuse, previous episodes of
pancreatitis and recurrent abdominal pain for at least 2 years,
the differential diagnosis between IPM and PC remains a clin-
ical dilemma. Moreover, if the IPM is caused by the autoim-
mune pancreatitis developed in the proximal pancreatic por-
tion and associated with obstruction of the common bile duct
and/or main pancreatic duct, the clinical and radiological di-
agnosis is evenmore difficult. As a consequence, patients with
the focal type of autoimmune pancreatitis often undergo sur-
gery [21].
MR imaging with MRCP is superior to both MR imaging
alone and CT in differentiating focal autoimmune pancreatitis
or another form of inflammatory pancreatic disease from car-
cinomas, considering that focal IPM tends to have an irregular
but not obstructed main pancreatic duct, which tends to pen-
etrate the mass after secretin administration. Moreover, in in-
flammatory masses the narrowing of the dilated duct tends to
be multiple and gradual, while in pancreatic cancer there is
usually a single abrupt interruption [22].
The so-called Bduct-penetrating sign^, defined as the pres-
ence of a stenosis of the main pancreatic duct coursing
through the mass, which enlarges after secretin administration,
has a sensitivity of 85 % and a specificity of 96 % for the
distinction between focal inflammatory mass and pancreatic
cancer (Figs. 6 and 7).
Carbognin et al. corroborate the importance of the SS-
MRCP sequence by showing a strong correlation be-
tween the duct-penetrating sign and the mass-forming
of autoimmune pancreatitis and an association between
the obstruction of the main pancreatic duct and pancre-
atic carcinoma. These characteristics improve the IPM
diagnosis if associated with other MR image findings,
such as delayed pancreatic enhancement and a capsule-
like smooth rim of the mass (an uncommon but
pathognomonic detail useful in differentiating IPM from
carcinoma) [23].
Cystic pancreatic lesions
Pancreatic cystic neoplasms (PCNs) are common lesions,
which in clinical practice are often detected incidentally.
Surgical indications for PCN are limited to symptomatic le-
sions and to lesions that are considered malignant or with a
potentially high risk of malignancy on the basis of the pre-
operative diagnostic assessment.
Main duct IPMN (MD-IPMN) is more frequently associat-
ed with this malignant transformation than is branch duct
IPMN (BD-IPMN). Because of the high malignant potential,
surgical resection is in general recommended for MD-IPMN,
whereas BD-IPMN management is more conservative with
imaging surveillance, especially in asymptomatic patients
with cysts measuring <3 cm and without features considered
worrisome for malignancy (e.g. mural nodules; thick, enhanc-
ing walls) [24].
BD-IPMN may show a more segmental cystic appearance
that can mimic the appearance of other cystic neoplasms of the
pancreas, such as non-neoplastic cysts. Thus, the main diag-
nostic challenge is to accurately distinguish IPMN from be-
nign cystic neoplasms of the pancreas such as serous
cystadenomas. In this scenario, the visualisation of the com-
munication between the BD-IPMN and the pancreatic duct
system is a key feature that allows us to distinguish IPMNs
from cystic lesions of other aetiologies. MRCP uses the al-
most stationary fluid in the biliary and pancreatic ductal sys-
tem as an intrinsic contrast medium that can be improved in
the detailed evaluation of the biliary and pancreatic ductal
anatomy of IPMN by administration of secretin [2, 12, 23].
Secretin allows for better visualisation of the ducts at MRCP
and improves the visibility of a communication between the
Fig. 5 a–c Inflammatory ampullary stenosis. MRCP obtained before
secretin administration (a) reveals distal common bile duct stenosis,
with consequent dilatation of extra-hepatic bile ducts. The head portion
of pancreatic duct is only slightly dilated. MRCP obtained 3 min after
secretin injection (b) shows increasing diameter of the pancreatic duct and
after 15 min (c) demonstrates duodenal filling up to genu inferius (grade
2), interpreted as reduced exocrine pancreatic reserve. Endoscopic
evaluation with papillary biopsy confirmed the diagnosis
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main pancreatic duct and the cystic lesion (Fig. 8) [23].
Moreover, secretin increases the cyst size or signal intensity
and permits better assessment of ductal irregularities.
However, the diagnostic utility of secretin in the diagnosis
of pancreatic cysts remains debated in part because there have
not been controlled studies assessing the added diagnostic
value of secretin [12, 25, 26].
Post-operative findings
Pancreato-jejunal anastomosis
Pancreatico-duodenectomy is among the most common sur-
geries performed for pancreatic pathology.
Although in-hospital mortality is now just a fraction of
what it once was, post-operative complication occurs in ap-
proximately 30–50 %.
While the bilio-enteric and entero-enteric strictures can be
addressed through minimally invasive endoscopic or radio-
graphic means, management of a pancreaticojejunal anasto-
mosis is challenging in that the altered anatomy of the post-
pancreaticoduodenectomy reconstruction often precludes suc-
cessful employment of such techniques.
The patency of pancreaticojejunostomy anastomosis is of
paramount importance in conserving the exocrine function of
the pancreas in patients who have undergone partial
pancreatectomy.
Indeed, permanent endocrine and exocrine dysfunctions
usually manifest within the first month of recovery, but a mi-
nor number of cases have been described as a long-term com-
plication of pancreaticoduodenectomy, demonstrating that
pancreatic insufficiency and atrophy of the pancreatic paren-
chyma are related to both post-surgical alteration of pancreatic
neurohormonal stimulator mechanisms and stenosis of the
pancreatojejunal anastomosis.
Early diagnosis is, therefore, needed to allow for immediate
endoscopic or surgical treatment.
Secretin MRCP proved to be a useful tool for diagnosis as
it allows for a ‘functional’ test of the remnant pancreas, and it
is more discriminating for ductal stenosis than is traditional
static MRCP [27].
The addition of secretin significantly improves the visual-
isation of the anastomotic site and allows the evaluation of the
post-secretin jejunal filling, which indicates relative preserva-
tion of pancreatic function (Fig. 9) [28].
Pancreatic transplantation
The aim of pancreas transplantation is to restore
normoglycaemia, curing diabetes and limiting the progression
of complications associated with diabetes. In the majority of
Fig. 6 a–e Autoimmune pancreatitis. Axial T2-weighted images (a, b)
show loss of the normal pancreatic lobulations at the level of the head and
focal obliteration of the pancreatic duct, better demonstrated on
conventional MRCP (c). After secretin administration (d, e) the stricture
detected in basal phase is solved (duct-penetrating sign)
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Fig. 8 a, b Branch duct-type
intraductal papillary mucinous
tumour in the uncinate process of
the pancreas. Conventional
MRCP (a) reveals a bilocular
cystic lesion without a sure
connection to the main pancreatic
duct. After secretin injection (b)
the pancreatic ductal system is
better delineated and it is also
possible to appreciate the
relationship between the lesion
and the Wirsung duct
Fig. 7 a–g Ductal adenocarcinoma. Axial T2-weighted (a, b) and axial
post-contrast T1-weighted images (c, d) show a small lesion at the level of
the pancreatic body with an abrupt cut-off of the main pancreatic duct,
better visualised on MRCP (e). After secretin stimulation (f, g) there is a
persistent stenosis, without the duct-penetrating sign
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cases, pancreas transplantation is performed in individuals
with type 1 diabetes that have end-stage renal disease, usually
with uraemia, retinopathy, progressive neuropathy and
hypoglycaemic unawareness. This procedure enables a total
restoration of endogenous secretion of insulin as well as re-
gression or stabilisation of the degenerative complications of
diabetes.
Despite the improvement in both surgical techniques and
post-operative management, there are significant complica-
tions following pancreas transplantation, particularly graft re-
jection. Graft loss through rejection occurs as a result of
alloimmunity or autoimmune recurrence; however, the latter
remains difficult to determine. Rejection rates are around
5 %–25 % depending on what immunosuppressive regime is
used.
The diagnosis of acute rejection can be established using
transplanted kidneys as surrogate markers if they are from the
same donor or direct biopsy of the pancreas in response to
changes in biochemical markers or clinical presentation; how-
ever, biopsy is frequently accompanied by complications,
such as inflammation of the gland, fistula of the main pancre-
atic duct and abdominal bleeding.
Various authors have tested MR imaging as a possible di-
agnostic non-invasive tool in the diagnosis of pancreatic graft
rejection. Allograft oedema due to acute rejection can be
recognised by means of increased T2 signal intensity; howev-
er, other causes of increased T2 signal include acute pancrea-
titis and ischaemia. There may be a substantial difference in
enhancement between rejecting and normal pancreas allo-
grafts; however, this finding is only moderately specific.
Dynamic MR pancreatography after secretin stimulation
has been shown to be a reliable diagnostic tool in the evalua-
tion of functional status of the pancreatic transplants in pa-
tients undergoing isolated or combined kidney–pancreas
transplantation [11]. After secretin administration, both varia-
tions in the diameter of the main pancreatic duct and graft fluid
outflow can be used to demonstrate the exocrine function of
the allograft (Fig. 10).
Asymptomatic elevation of serum lipase and amylase
Chronic asymptomatic pancreatic hyperenzymaemia (al-
so called BGullo’s syndrome^) [29, 30] is a persistent
abnormal increase in the serum concentrations of the
pancreatic enzymes without pancreatic symptoms and
evidence at imaging of pancreatic diseases. The medical
need in these patients is to differentiate undiagnosed
pancreatic disease and other extra-pancreatic conditions
that may induce an increase in serum concentrations of
amylase and lipase, including chronic viral hepatitis,
renal failure, celiac disease, inflammatory bowel disease,
hyperparathyroidism and neoplasms [21, 31]. Consistent
evidence, however, indicates that asymptomatic subjects
with increased pancreatic enzymes lasting for more than
2 years and accompanied by thoroughly negative imag-
ing tests (pancreatic CT scan and/or MRCP) are indeed
affected by benign pancreatic hyperenzymaemia [30].
SS-MRCP is the most appropriate imaging technique
for investigating patients with chronic asymptomatic
pancreatic hyperenzymaemia [21, 31]. The most
Fig. 9 a–e
Pancreaticoduodenectomy. Axial
T2w (a) and MIP (b) images
show the pancreatic body and tail
with slight and irregular dilation
of the main pancreatic duct.
Secretin-stimulated MRCP (c–e)
exhibits patency of anastomotis
with normal filling of jejunal
loops well
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frequent abnormalities diagnosed on secretin-enhanced
MRCP images were diffusely dilated side branches
(25.6 %), diffuse main pancreatic duct dilation and de-
layed emptying of the main pancreatic duct (14.4 %)
[21]. A possible explanation for these alterations may
be a delayed emptying of the pancreatic outflow, not
able to trigger pancreatitis but sufficient to induce a
disorder of the normal pancreatic intracellular exocytosis
process and, therefore, a leakage of pancreatic enzymes
into the blood through the basolateral membrane of the
acinar cell.
In a study by Donati et al. [32] in 80 asymptomatic
patients with persistent (for at least 6 months) non-
specific serum hyperamylasaemia and hyperlipasaemia,
conventional MRCP showed pancreatic abnormalities
only in 50 % of patients, while, after secretin stimula-
tion, the percentage of detection of pancreatic alterations
was increased by 27.5 %. SS-MRCP may represent the
best noninvasive diagnostic technique since it gives
morphological and functional information on the pancre-
as, which has been found to be abnormal in 68.7 % of
patients.
Pancreatic trauma
Pancreatic injury in the setting of blunt abdominal trauma is
uncommon, with reported incidence ranging from approxi-
mately 2 % to 12 %. The associated mortality is considerable,
however, and may be as high as 30 % to 50 %, largely sec-
ondary to concomitant injuries.
Elevated serum amylase may be present, but the clini-
cal presentation of pancreatic injury is variable and non-
specific. Blunt pancreatic injuries occur more commonly
in the body of the gland, accounting for two-thirds of
cases, and are typically caused by a crushing impact
against the vertebral column.
Because the main cause for morbidity and mortality
is disruption of the MPD, assessment for ductal injuries
is critical [32].
Disruption was defined as a discontinuity in the duct or,
better, the visualisation of increasing amounts of fluid out-
side the duct or proximal small bowel after secretin
stimulation. Apparent duct discontinuity in patients with
pancreatitis can have a number of causes, including compression
of the duct by fibrosis or oedema, strictures, stones or adjacent
magnetic susceptibility artefacts from gas, haemosiderin or
metal [32].
The causes of pancreatic duct disruption also include acute
pancreatitis, chronic pancreatitis and surgery [33].
Persistent disruption can result in fluid collections,
ascites or fistulas and has a significant impact on the
clinical course. Small side-branch disruptions can heal
without long-term sequelae, but main-duct disruption
can result in strictures, secondary recurrent acute pan-
creatitis, pancreatic atrophy, and eventually endocrine
and exocrine insufficiency.
Current treatment options include surgery, endoscopic in-
tervention or conservative management. Timely diagnosis of
duct disruption, its location and the size of the leak are essential
for choosing the appropriate treatment.
Fig. 10 a–e Pancreatic transplant. On MRCP before secretin administration (a) the main pancreatic duct of the graft is not appreciable; however after
secretin injection (b, c) it is possible to recognise both the Wirsung duct (arrows) and the normal duodenal-jejunal graft filling
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The clinical setting, ductal anatomy and parenchymal anat-
omy also affect the choice of therapy.
Cross-sectional imaging can be used to infer the presence
and degree of disruption, although CT can be unreliable in the
early diagnosis of pancreatic trauma.
Deep lacerations (involving greater than 50 % of the thick-
ness of the pancreas) are predictive of ductal disruption and
may be detected using T1-weighted post-contrast and T2-
weighted sequences [32].
MRCP has been used in trauma patients to show
peripancreatic fluid collections and the ductal anatomy, but
only ERCP has been able to provide dynamic information as
to whether there is continuing leakage from the duct. Even
then, ERCP fails to reveal the disruption in as many as 25 %
of instances and also carries the risk of introducing infection
and the theoretic risk of exacerbating a leak by contrast injec-
tion at non-physiologic pressures.
Non-visualisation of a disruption is more likely to result in
therapeutic failure, either surgical or endoscopic, and ERCP
may fail to show the disruption because of duct obstruction
proximal to it, and overfilling of the duct in pancreatic disrup-
tion is actively discouraged because of the risk of sepsis.
SS-MRCP is a non-invasive technique that can show: a) the
whole pancreatic anatomy, both the parenchyma and the
ducts; b) any peripancreatic fluid collections; c) disruption,
including a leak, beyond an obstructed duct. SS-MRCP thus
provides all the information available from CT plus a more
complete assessment of the duct than often can be obtained on
ERCP and dynamic information about ongoing leakage.
One caveat is that percutaneous drains should be clamped
before SS-MRCP and the abdomen should be examined for
any sinus tracts, which need to be monitored clinically or
included in the images [33, 34].
Conclusion
Secretin-enhanced MR cholangiopancreatography is a non-
invasive imaging technique that usually improves the visual-
isation of the pancreatic ductal system. In particular, it can
accurately depict the morphologic features and calibre modi-
fications of the main pancreatic duct and side branches, and it
can evaluate pancreatic flow dynamics through the duodenal
papillae and duodenal filling after secretin stimulation.
Secretin increases the diagnostic capabilities of MRCP in
various pancreatic diseases and can be indicated in patients
with known or suspected anatomic variants, sphincter of Oddi
dysfunction, chronic pancreatitis, main pancreatic duct steno-
sis, cystic pancreatic lesions, pancreatic trauma, chronic
asymptomatic hyperenzymaemia and post-operative condi-
tions such as pancreato-jejunal anastomosis and pancreatic
transplantation.
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